Wells Fargo
YMAB

Wells Fargo’s Y-mAbs Therapeutics YMAB Stock Holding History

Wells Fargo’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,037
Closed -$85.9K – 7445
2025
Q2 		$85.9K Buy
19,037
+1,185
+7% +$5.33K ﹤0.01% 5285
2025
Q1 		$79.1K Buy
17,852
+394
+2% +$2.29K ﹤0.01% 5218
2024
Q4 		$137K Buy
17,458
+6,131
+54% +$74.7K ﹤0.01% 5016
2024
Q3 		$149K Sell
11,327
-449
-4% -$5.69K ﹤0.01% 4767
2024
Q2 		$142K Sell
11,776
-239
-2% -$3.23K ﹤0.01% 4735
2024
Q1 		$195K Buy
12,015
+1,582
+15% +$21.3K ﹤0.01% 4480
2023
Q4 		$71.2K Buy
10,433
+2,202
+27% +$12.7K ﹤0.01% 5106
2023
Q3 		$44.9K Sell
8,231
-6,387
-44% -$37.2K ﹤0.01% 5235
2023
Q2 		$99.3K Buy
14,618
+7,549
+107% +$56.6K ﹤0.01% 5043
2023
Q1 		$35.4K Buy
+7,069
New +$28.9K ﹤0.01% 5353
2022
Q4 		– Sell
-1,291
Closed -$18K – 7774
2022
Q3 		$18K Sell
1,291
-242
-16% -$4.01K ﹤0.01% 5460
2022
Q2 		$23K Sell
1,533
-16,354
-91% -$191K ﹤0.01% 5389
2022
Q1 		$212K Sell
17,887
-11,078
-38% -$114K ﹤0.01% 4946
2021
Q4 		$470K Sell
28,965
-13,158
-31% -$281K ﹤0.01% 4713
2021
Q3 		$1.2M Buy
42,123
+25,523
+154% +$804K ﹤0.01% 4085
2021
Q2 		$562K Buy
16,600
+2,226
+15% +$71.5K ﹤0.01% 4558
2021
Q1 		$435K Sell
14,374
-12,511
-47% -$513K ﹤0.01% 4754
2020
Q4 		$1.33M Buy
26,885
+10,461
+64% +$484K ﹤0.01% 3806
2020
Q3 		$632K Sell
16,424
-1,884
-10% -$75K ﹤0.01% 4178
2020
Q2 		$791K Buy
18,308
+5,720
+45% +$216K ﹤0.01% 4001
2020
Q1 		$329K Buy
12,588
+1,606
+15% +$46.6K ﹤0.01% 4356
2019
Q4 		$343K Sell
10,982
-15,690
-59% -$464K ﹤0.01% 4647
2019
Q3 		$695K Buy
26,672
+7,469
+39% +$191K ﹤0.01% 4133
2019
Q2 		$438K Buy
19,203
+15,526
+422% +$357K ﹤0.01% 4468
2019
Q1 		$96K Buy
3,677
+77
+2% +$1.69K ﹤0.01% 5141
2018
Q4 		$70K Buy
+3,600
New +$82.7K ﹤0.01% 5427

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's YMAB Position: Q3 2025 in Review

Wells Fargo sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 19,037 shares — an estimated $85.9K sold.

Wells Fargo first reported a position in YMAB in Q4 2018 and held it in 26 quarters. The position peaked at $1.33M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Wells Fargo reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 19,037 Y-mAbs Therapeutics shares in Q3 2025, an estimated $85.9K.
  • Wells Fargo first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 26 quarters.
  • Wells Fargo's Y-mAbs Therapeutics position peaked at $1.33M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.